RE: Webcast currently showing25 May 2022 14:15
I didn't get to see the presentation.
Fundamentally the drug needs another trial. This was true immediately after the Sprinter results and with just 110 Activ 2 patients dosed, even if that data is very good, it cannot proceed to market.
I have kept my SNG shares and for the long haul I suppose. We could get a takeover and that would suit me as it provides closure and perhaps a small profit. Good luck all.